American College of Chest Physicians

The addition of a couple of new drug classes at the turn of the century have given clinicians the greenlight to stack therapies at initial treatment.

There’s a challenge to achieve control in some asthma patients since the disease is heterogenous—both allergic and non-allergic triggers can initiate Type 2 inflammatory pathways that can drive pathology.

Joshua Denson, MD, MS, discusses the comorbidities associated with asthma.

Now that real-world data registries are being compiled, the constriction-limiting drug class is now going through personalizations including new titration strategies.

Antonion R. Anzueto, MD, covers the latest research regarding biomarkers in COPD, outlining possible avenues of investigation and addressing regional causes of the disease.

Conflict management education intervention, which includes elements of compromise and awareness, helps improve ICU care.

What makes the monoclonal antibody so enticing to the asthma community?

A 200 mg dose of the monoclonal antibody was also shown to significantly reduce ashtma exacerbations over 1 year versus placebo.

A retrospective review of rural region's hospitals found that even the discharge time of day could be associated with a greater chance of readmission.

Investigators from Brooke Army Medical Center discuss pharmacological and non-pharmacological treatment strategies for tobacco cessation.

Gram-negative bacteria excluding Pseudomonas Aeruginosa has been associated with greater rates of patient mortality, vasopressor administration, and ICU admission.

Investigators found that treating for CSA in the patient population significantly decreases mortality risk—despite previous clinical warnings.

Secondhand factors in asthma, such as environmental exposures like pets and secondhand smoke, are not significant in overall disease improvement.

Investigators have shared new disparities of characteristics in men and women with differing severities of respiratory arousal threshold.

Women are less likely to be administered lung protective tidal volumes (TVs) when being considered as a lung donor.

More IMPACT trial results shows Trelegy Ellipta has benefits for both reversible and nonreversible COPD patients in exacerbations and lung function versus dual therapy.

Data show that while women are underrepresented as fellows of the American College of Chest Physicians, the volume of women applying is increasing.

A new study found that Medicare Part D formulary shifts sometimes result in asthma patients forgoing controller therapy altogether.

The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.

Gordon L. Yung, MD, FCCP, explains the right patient perspective of the antifibrotic therapy.

Almost 500 patients were split into 4 dosing groups for JZP-110.

Researchers studied recently-referred COPD patients and what attributes put them at risk for poor inhaler device technique.

Many of the symptoms of VTE are normal during pregnancy, and it's difficult to find a suitable population to test out new diagnostic and therapeutic methods.

There's a medical emergency in one in every 604 flights. Here's what doctors need to know so they can handle them appropriately.

Two consecutive CHEST studies showed combination therapy's expanding portfolio.

Commercial drivers are very unlikely to admit to symptoms that might result in loss of working time and money. That's where their primary care physicians come in.

Telemedicine is extraordinarily promising for patients and practitioners, but there are lingering challenges that are keeping it from reaching its full potential.

Telemedicine is more than just a trend in medicine – it's one of the most potent tools available to health systems and patients alike.

Regeneron and Sanofi released more positive phase 3 trial results, a day following phase 2b results were shared at CHEST.

Clinicians now have pharmacologic and nonpharmacologic treatments that can be very effective for the common condition.